Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the potential effectiveness of a hair loss treatment called pyrilutamide. One person has been using it since September and reports positive results.

The user is seeing progress in hair regrowth using a combination of 8% minoxidil, 0.25% dutasteride, and 0.01% tretinoin. The conversation includes comments on the effectiveness and application of these treatments.

A user shared their experience 36 days after a hair transplant of 5500 grafts in Delhi, using topical minoxidil and finasteride, and plans to start oral finasteride. They reported less shedding than expected and strong early growth, while also maintaining a healthy lifestyle.

Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.

Ordering Pyrilutamide from Minoxidilmax to use as an experimental topical treatment for hair loss, with discussion of the carrier used in trials and encouragement from other users.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The user has been using finasteride and dutasteride mesotherapy for 2 months with no noticeable change in hair loss or shedding. They experienced side effects from oral minoxidil and suspect seborrheic dermatitis.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation discusses hair loss and the ineffectiveness of a treatment called pyrilutamide, with one user experiencing negative results and questioning the product's authenticity.

People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.

A user's hair loss treatment progress over the last 6 months using finasteride, minoxidil and dermarolling; other users have commented to ask questions or share their own experiences.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

A user's 12-month progress using RU58841, dutasteride, and minoxidil for hair loss. The user is open to answering questions via direct message.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The user has been using topical minoxidil 5% and oral dutasteride for 2 months and is seeking feedback on progress. Responses suggest small growth and recommend waiting longer for more noticeable results.

The conversation is about a person's slow progress in treating hair loss using finasteride, microneedling, testosterone replacement therapy, dutasteride, RU58841, and minoxidil. They experienced a significant hair shed after adding dutasteride.

The conversation is about a person's hair improvement after 14.5 months using RU58841 and Minoxidil topically at 50 mg each day, with noticeable hairline improvement but incomplete crown area recovery. The person struggles to take good pictures of their crown area.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.

The user experienced constipation and gas issues possibly linked to Minoxidil and Dutas use, leading them to stop and later restart Minoxidil without lactose. They recently began using finasteride and are awaiting a SIBO test to understand their gastrointestinal issues.

Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

The user experienced hair regrowth after 5 months on 5 mg oral minoxidil and 1 mg dutasteride, following a year of ineffective finasteride use. They noticed progress after an initial shedding phase and hope for further improvement, with expectations of near-max regrowth around 18 months.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.